论文部分内容阅读
个体化治疗是早期乳腺癌最佳的治疗方法。每个肿瘤都有其不同的特点,同样临床和病理特点的肿瘤常有不同的预后和对治疗的不同反应,这些不同都在肿瘤的基因组中编码,所以寻找到某种有效的生物因子在评估肿瘤的行为和风险时就可以替代或补充临床和病理学标记物。高通量基因测序的发展使研究肿瘤基因的表达成为可能,肿瘤指纹可以更准确得预测疾病的病程和对治疗的反应,本综述主要分析了多基因谱分析在早期乳腺癌预测预后和疗效作用,特别是mamllmaprint和鹿特丹信号的作用,还有Oncotype Dx在他莫昔芬治疗过的病人中的应用,以及化疗药物与预测基因的关系。这将有助于乳腺癌患者临床决策的改进。
Individualized treatment is the best treatment for early breast cancer. Each tumor has its own different characteristics, the same clinical and pathological features of the tumor often have different prognosis and different response to treatment, these differences are encoded in the tumor genome, so find a valid biological factors in the assessment Tumor behavior and risk can be replaced or supplemented with clinical and pathological markers. The development of high-throughput gene sequencing makes it possible to study the expression of tumor genes. The fingerprint of the tumor can predict the course of the disease and the response to the treatment more accurately. This review mainly analyzes the prognostic and curative effects of multiple gene analysis in early breast cancer , In particular the role of mamllmaprint and the Rotterdam signal, the use of Oncotype Dx in patients treated with tamoxifen, and the relationship between chemotherapeutic drugs and predicted genes. This will help improve the clinical decision-making of breast cancer patients.